Fig. 3
From: Tamoxifen activity against Plasmodium in vitro and in mice
Tamoxifen has antiplasmodial activity in vivo and inhibits experimental cerebral malaria in mice. CB57/B6 mice were treated with tamoxifen 40 mg/kg per day 1 week prior infection with P. berghei ANKA and during the course of the infection (squares) versus untreated control group (circles). Animals treated with tamoxifen exhibited lower parasitaemia levels (a), lower neurological signs of cerebral malaria (b) and a 100% survival ratio after 7 days post-infection (c) compared with control group. Statistical significance was calculated using an unpaired t test (a, b) or Log-rank (Mantel–Cox) test (c) (*p < 0.05; ***p < 0.01; ****p < 0.0001)